TOPICALLY & TRANSDERMALLY STUDIED PEPTIDES / COLOPHON
About This Research Desk
An independent, citation-anchored orientation to research peptide fundamentals — not a vendor, not a clinic, not medical advice.
What Topical Peptides is
Topical Peptides is an independent editorial reference desk built around a single organizing question: how does a given research peptide actually get into, or onto, the body — and what does that route reveal about how it works? The desk covers three peptides that answer that question in three different ways: GHK-Cu, a copper-binding tripeptide with a directly measured transdermal delivery story, leads the desk; semaglutide, a GLP-1 receptor agonist built for the bloodstream, and thymosin alpha-1, a thymic immune peptide delivered exclusively by injection, provide the contrast.
The idea is not that these three compounds treat the same condition or share a mechanism — they plainly do not. The idea is that reading them together turns delivery route from an afterthought into a genuine fundamentals lesson: why some peptides can be rubbed onto skin and measured crossing it, why others need a fatty-acid side chain and a week-long half-life just to survive in blood, and why others are studied exclusively by injection because their targets were never reachable any other way. Each compound has its own page; a comparison page lines up the three side by side; and a single shared references list aggregates every source used across the site.
How it is compiled
Two principles govern what appears here. First, every research claim is anchored to a numbered citation on the references page — peer-reviewed journal articles and clinical-trial publications, with DOIs and PubMed links where available. Where a finding comes from a review rather than a primary study, or from a database analysis rather than a directly measured tissue outcome, that distinction is stated in the same sentence, not buried in a footnote.
Second, the evidence is described at its actual strength and scale. GHK-Cu's human evidence comes from small controlled trials — some in the tens of participants — alongside extensive cell-culture and gene-expression work; semaglutide's comes from multi-thousand-participant randomized trials; thymosin alpha-1's is the most mixed, spanning decades of smaller positive signals and one large, rigorous, null 2025 trial. This desk does not average those differences away or present them as equivalent; it says plainly which kind of evidence supports which claim.
What it is not
Topical Peptides is not a pharmacy, a clinic, or a seller of any kind. It does not sell, source, or broker GHK-Cu, semaglutide, thymosin alpha-1, or anything else, and it has no affiliate relationship with any manufacturer, telehealth provider, or research-chemical supplier. It does not diagnose conditions, prescribe treatment, or recommend a dose, schedule, or route of administration for any person.
Semaglutide is an approved prescription medicine available only through licensed medical providers. Thymosin alpha-1 is approved as a drug in some countries but not in the United States, where it is investigational. GHK-Cu is a legal cosmetic ingredient in its topical form; any other route is unapproved and unstudied in humans. Readers seeking clinical guidance should consult a licensed healthcare provider. Editorial correspondence about citations, corrections, or newly published research can be directed to the contact page; this desk cannot respond to requests for medical advice.